Analyzing ANI Pharmaceuticals (NASDAQ:ANIP) & Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Corcept Therapeutics and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Risk & Volatility

Corcept Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Corcept Therapeutics and ANI Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	2	5	0	2.50
ANI Pharmaceuticals	0	5	3	0	2.38

Corcept Therapeutics presently has a consensus target price of $138.17, indicating a potential upside of 22.34%. ANI Pharmaceuticals has a consensus target price of $98.00, indicating a potential upside of 31.67%. Given ANI Pharmaceuticals’ higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Corcept Therapeutics.

Earnings & Valuation

This table compares Corcept Therapeutics and ANI Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	16.03	$99.65 million	$0.42	268.90
ANI Pharmaceuticals	$883.37 million	1.94	$78.34 million	$4.64	16.04

Corcept Therapeutics has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Corcept Therapeutics beats ANI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.